/biz/ - Business & Finance

>>55476159
>This does not reveal anything about the dose dependent side effects.
Yeah I had issues with posting for some reason. that picture i posted demonstrates that there's a lot of issues with the drug’s pharmacokinetics (pk) since they showed no increased exposure past 20 mg. In Phase 2 studies they had 6 discontinuations of 43 patients but that was dosing at 10 mg titrating up to 20/30. They’re starting at 40mg in this Phase 3 and going to 60mg.
> Where are you getting the information that it is unsafe
Not dose specific. The company is doing really wacky things with the dosing actually. I trust the pk over a post-hoc dose response obviously